Latest news

  • Jun 17, 2022 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) View
  • Jun 13, 2022 Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors View
  • Jun 08, 2022 Iovance Biotherapeutics to Present at Upcoming Conferences View
View All News

Clinical platforms

Our T-cell-based immunotherapy technology platforms are potentially applicable to many solid tumor types and blood cancers. Each platform is focused on leveraging patient-specific cells to recognize and attack diverse cancer cells that are unique to each patient. Unlike targeted cell therapies that act on shared antigen targets common to certain tumors, our polyclonal T cells are personalized therapies that can target a variety of neoantigens (new proteins generated by tumor mutations) that are unique to the patient or tumor.

TIL therapy is our lead T-cell-based immunotherapy platform. We are currently investigating TIL therapy in clinical trials in multiple advanced solid tumor cancers. We are also advancing genetically modified TIL therapies as a next-generation approach for solid tumor cancers.

Our peripheral blood lymphocyte (PBL) therapy platform for blood cancers is based on polyclonal T cells that are collected, amplified and reinvigorated from a patient’s blood sample.


Iovance Cell Therapy Center (iCTC)

Our investigational TIL therapy is manufactured at our state-of-the-art, 136,000–square-foot Cell Therapy Center, located in Philadelphia, PA, using proprietary good manufacturing practices (GMP).

TIL and PBL therapies are investigational therapies and have not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of these therapies have not been determined.